BioCryst Pharmaceuticals, Inc. (BCRX) |
|
7.385 0.015 (0.2%)
|
09-26 15:40 |
|
Open: |
7.36 |
Pre. Close: |
7.37 |
|
High:
|
7.59 |
Low:
|
7.32 |
|
Volume:
|
1,182,999 |
Market Cap:
|
1,399(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 3:17:41 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 9.13 One year: 10.66 |
| Support: |
Support1: 7.11 Support2: 6.67 |
| Resistance: |
Resistance1: 7.82 Resistance2: 9.13 |
| Pivot: |
7.12  |
| Moving Average: |
MA(5): 7.27 MA(20): 7.11
MA(100): 7.53 MA(250): 9.39 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 60.8 %D(3): 53.6 |
| RSI: |
RSI(14): 54.9 |
| 52-week: |
High: 14.5 Low: 6.61 |
| Average Vol(K): |
3-Month: 2,518 (K) 10-Days: 2,907 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BCRX ] has closed below upper band by 23.9%. Bollinger Bands are 8.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.58 - 7.61 |
7.61 - 7.64 |
|
Low:
|
7.11 - 7.14 |
7.14 - 7.17 |
|
Close:
|
7.31 - 7.37 |
7.37 - 7.42 |
|
Company Description |
|
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. |
Headline News |
Tue, 26 Sep 2023
RBC Capital Reiterates Biocryst Pharmaceuticals (BCRX ... - Nasdaq
Thu, 21 Sep 2023
Can BioCryst Pharmaceuticals Inc (BCRX) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver
Tue, 19 Sep 2023
INESSS Recommends Public Reimbursement for BioCryst’s ... - BioSpace
Mon, 18 Sep 2023
RBC Capital Upgrades BioCryst Pharmas Status and Raises Price ... - Best Stocks
Mon, 11 Sep 2023
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average ... - MarketBeat
Tue, 05 Sep 2023
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
189 (M) |
| Shares Float |
159 (M) |
|
% Held by Insiders
|
1.2 (%) |
|
% Held by Institutions
|
93.6 (%) |
|
Shares Short
|
41,300 (K) |
|
Shares Short P.Month
|
39,000 (K) |
Stock Financials |
|
EPS
|
-1.3 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-2.05 |
|
Profit Margin (%)
|
-79.2 |
|
Operating Margin (%)
|
-36.9 |
|
Return on Assets (ttm)
|
-13.6 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
25.8 |
|
Gross Profit (p.s.)
|
0.05 |
|
Sales Per Share
|
1.61 |
|
EBITDA (p.s.)
|
-0.59 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-123 (M) |
|
Levered Free Cash Flow
|
-111 (M) |
Stock Valuations |
|
PE Ratio
|
-5.7 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
-3.61 |
|
Price to Sales
|
4.57 |
|
Price to Cash Flow
|
-11.44 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
